Inventiva (NASDAQ:IVA) Shares Gap Up - Here's Why

Key Points

• Inventiva S.A. Sponsored ADR shares gapped up from $5.36 to $5.64 and last traded at $5.57, reflecting a trading increase of 3.5%.
• Several equities research analysts have given the stock an average rating of "Moderate Buy" with an average target price of $14.83, including upgrades from Piper Sandler and HC Wainwright.
• An institutional investor recently acquired a new position in Inventiva, purchasing 10,715 shares valued at approximately $32,000, indicating growing institutional interest in the company.

Inventiva S.A. Sponsored ADR (NASDAQ:IVA - Get Free Report) gapped up before the market opened on Wednesday . The stock had previously closed at $5.36, but opened at $5.64. Inventiva shares last traded at $5.57, with a volume of 8,593 shares traded.

Analyst Ratings Changes

IVA has been the topic of several analyst reports. HC Wainwright initiated coverage on shares of Inventiva in a research report on Wednesday, September 3rd. They set a "buy" rating and a $20.00 price target on the stock. Guggenheim boosted their target price on Inventiva from $9.00 to $13.00 and gave the stock a "buy" rating in a report on Tuesday, September 2nd. Finally, Piper Sandler started coverage on Inventiva in a report on Wednesday, August 27th. They set an "overweight" rating and a $26.00 target price on the stock. Five research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company's stock. According to data from MarketBeat, the company has an average rating of "Moderate Buy" and a consensus price target of $14.83.

Inventiva Stock Down 2.8%

The business has a fifty day simple moving average of $4.15 and a 200 day simple moving average of $3.56.

Institutional Trading of Inventiva

An institutional investor recently raised its position in Inventiva stock. Wealth Enhancement Advisory Services LLC lifted its stake in shares of Inventiva S.A. Sponsored ADR (NASDAQ:IVA - Free Report) by 54.5% during the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 16,558 shares of the company's stock after purchasing an additional 5,843 shares during the quarter. Wealth Enhancement Advisory Services LLC's holdings in Inventiva were worth $50,000 as of its most recent SEC filing. Institutional investors and hedge funds own 19.06% of the company's stock.

Inventiva Company Profile

Inventiva SA, a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases. Its lead product candidate is Lanifibranor, which is in Phase III clinical trial to treat NASH. The company also develops Odiparcil for the treatment of patients with mucopolysaccharidoses type VI.